Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.
Streinu-Cercel A, Castagna A, Chang SC, Chen YS, Koullias Y, Mozaffarian A, Hyland RH, Humeniuk R, Caro L, Davies S, Rodriguez L, Hedskog C, Chen S, Etchevers K, Behenna-Renton N, Llewellyn J, Osinusi A, Duff F, Barrat Hernández A, McNally D, Simon-Campos JA, Leal FE, Fouche LF, González Del Castillo JM. Streinu-Cercel A, et al. Among authors: hedskog c. Clin Infect Dis. 2025 Jul 22:ciaf406. doi: 10.1093/cid/ciaf406. Online ahead of print. Clin Infect Dis. 2025. PMID: 40694627
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
Ogbuagu O, Goldman JD, Gottlieb RL, Singh U, Shinkai M, Acloque G, Fusco DN, Gonzalez E, Kumar P, Luetkemeyer A, Lichtman A, Mozaffarian A, Koullias Y, Hyland RH, Llewellyn J, Osinusi A, Duff F, Humeniuk R, Caro L, Davies S, Rodriguez L, Hedskog C, Chen S, Etchevers K, Nadig P, Kohli A; OAKTREE Trial Investigators. Ogbuagu O, et al. Among authors: hedskog c. Lancet Infect Dis. 2025 Dec;25(12):1282-1292. doi: 10.1016/S1473-3099(25)00238-5. Epub 2025 Jul 14. Lancet Infect Dis. 2025. PMID: 40675167 Clinical Trial.
Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys.
Pitts J, Zamora JLR, Manhas S, Aeschbacher T, Chan J, Cutillas V, Nair V, Riola NC, Vijjapurapu A, Vermillion MS, Eng S, Richards C, Han D, Perry JK, Chaudhuri S, Liu SW, Martinez C, Peinovich N, Sun KH, Cai A, Martin R, Moshiri J, Hedskog C, Babusis D, Siegel DS, Kalla R, Avadhanula V, Piedra PA, Stobbelaar K, Delputte PL, Marceau C, Mateo R, Maiorova E, Mo H, Subramanian R, Mackman RL, Cihlar T, Fletcher SP, Bilello JP. Pitts J, et al. Among authors: hedskog c. Nat Commun. 2025 Jul 11;16(1):6437. doi: 10.1038/s41467-025-61595-3. Nat Commun. 2025. PMID: 40645925 Free PMC article.
A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques.
Zumbrun EE, Garvey CB, Wells JB, Lynn GC, Van Tongeren SA, Steffens JT, Wetzel KS, Wetzel DL, Esham HL, Garza NL, Lee ED, Scruggs JL, Rossi FD, Brown ES, Weidner JM, Gomba LM, O'Brien KA, Jay AN, Zeng X, Akers KS, Kallgren PA, Englund E, Meinig JM, Kugelman JR, Moore JL, Bloomfield HA, Norris SL, Bryan T, Scheuerell CH, Walters J, Mollova N, Blair C, Babusis D, Cihlar T, Porter DP, Singh B, Hedskog C, Bavari S, Warren TK, Bannister R. Zumbrun EE, et al. Among authors: hedskog c. Viruses. 2024 Dec 18;16(12):1934. doi: 10.3390/v16121934. Viruses. 2024. PMID: 39772240 Free PMC article.
SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.
Rodriguez L, Lee HW, Li J, Martin R, Han D, Xu S, Moshiri J, Peinovich N, Camus G, Perry JK, Hyland RH, Porter DP, Abdelghany M, Götte M, Hedskog C. Rodriguez L, et al. Among authors: hedskog c. Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0123824. doi: 10.1128/aac.01238-24. Epub 2024 Dec 19. Antimicrob Agents Chemother. 2025. PMID: 39699245 Free PMC article. Clinical Trial.
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials.
Hedskog C, Spinner CD, Protzer U, Hoffmann D, Ko C, Gottlieb RL, Askar M, Roestenberg M, de Vries JJC, Carbo EC, Martin R, Li J, Han D, Rodriguez L, Parvangada A, Perry JK, Ferrer R, Antón A, Andrés C, Casares V, Günthard HF, Huber M, McComsey GA, Sadri N, Aberg JA, van Bakel H, Porter DP. Hedskog C, et al. Viruses. 2024 Mar 31;16(4):546. doi: 10.3390/v16040546. Viruses. 2024. PMID: 38675889 Free PMC article. Clinical Trial.
Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study.
Ahmed A, Munoz FM, Muller WJ, Agwu A, Kimberlin DW, Galli L, Deville JG, Sue PK, Mendez-Echevarria A, Humeniuk R, Guo S, Rodriguez L, Han D, Hedskog C, Maxwell H, Palaparthy R, Kersey K, Rojo P; CARAVAN Study Investigators. Ahmed A, et al. Among authors: hedskog c. Pediatrics. 2024 Mar 1;153(3):e2023063775. doi: 10.1542/peds.2023-063775. Pediatrics. 2024. PMID: 38332740 Clinical Trial.
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.
Mackman RL, Kalla RV, Babusis D, Pitts J, Barrett KT, Chun K, Du Pont V, Rodriguez L, Moshiri J, Xu Y, Lee M, Lee G, Bleier B, Nguyen AQ, O'Keefe BM, Ambrosi A, Cook M, Yu J, Dempah KE, Bunyan E, Riola NC, Lu X, Liu R, Davie A, Hsiang TY, Dearing J, Vermillion M, Gale M Jr, Niedziela-Majka A, Feng JY, Hedskog C, Bilello JP, Subramanian R, Cihlar T. Mackman RL, et al. Among authors: hedskog c. J Med Chem. 2023 Sep 14;66(17):11701-11717. doi: 10.1021/acs.jmedchem.3c00750. Epub 2023 Aug 19. J Med Chem. 2023. PMID: 37596939 Free PMC article.
43 results